Clinical Research

Rznomics Secures FDA RMAT Designation For RNA Editing Therapy RZ 001 In Liver Cancer

RMAT designation based on promising Phase 1b/2a clinical data, including safety profile and preliminary response rates, ...

 May 11, 2026 | News

Harbour BioMed Secures US FDA Clearance For Phase I Trial Of Bispecific Cancer Antibody HBM7004

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...

 May 11, 2026 | News

ACROBiosystems Simplifies Global HEK293 Licensing To Accelerate Biopharma R&D Compliance

ACROBiosystems has implemented a major upgrade to its global licensing framework for HEK293 functional cell lines, transitioning from a complex administrat...

 May 11, 2026 | News

ABEC Expands Process Sciences Capabilities To Accelerate Bioprocess Development And Scale Up

 ABEC, a global leader in bioprocess engineering solutions, announced the expansion of its Process Sciences group, expanding its ability to ...

 May 08, 2026 | News

Taimei Technology And C&R Research Partner To Advance AI Driven Clinical Trial Operations In South Korea

Taimei Technology (HK.02576), a leading AI-powered drug clinical development platform company, and C&R Research (A359090), a top-tier CRO in South Kore...

 May 08, 2026 | News

Thermo Fisher Introduces Gibco CTS DynaXS Single Use Bioreactor For Scalable Cell Therapy Manufacturing

New Gibco™ CTS™ DynaXS™ Single Use Bioreactor supports flexible, cGMP-ready cell expansion from process development to clinical productio...

 May 05, 2026 | News

EnGeneIC Doses First Patient In Trial Targeting Recurrent Glioblastoma

EnGeneIC announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s investigational EGFR-targeted EDV™ (EnGene...

 May 05, 2026 | News

Australia Approves First RNAi Therapy For Familial Chylomicronemia Syndrome

– REDEMPLO is the first and only medicine approved for use in the treatment of FCS in Australia, and is authorized for both genetically confirmed a...

 May 05, 2026 | Report

Restore Vision Reports Encouraging Phase I II Data For RV 001 Gene Therapy In Retinitis Pigmentosa

Phase I/II clinical trial interim results, out to 168 days, from the two RV-001 dosing cohorts with advanced Retinitis Pigmentosa are presented at key Ma...

 May 04, 2026 | News

Lakewood Amedex Advances Nu 3 Bisphosphocin Candidate With Strong AMR Resistance Profile

Nu-3 represents a novel class of potent, fast-acting, broad-spectrum antimicrobials called Bisphosphocins® Lakewood-Amedex Biotherapeutics Inc., (NASD...

 May 04, 2026 | News

ACROBiosystems And SeromYx Partner To Advance Functional Profiling Of Anti CD20 Antibodies

ACROBiosystems, a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries, has entered into a research collabora...

 May 01, 2026 | News

Formosa Pharmaceuticals And SERI Partner To Advance Next Generation Ophthalmic Therapies

    The collaboration aims to address significant unmet needs in the treatment of corneal and ocular surface diseases. By combining innovative ...

 May 01, 2026 | News

HistoIndex Expands US Clinical Network With New Hepatology And Gastroenterology Partnerships

HistoIndex, a pioneer in AI-driven digital pathology solutions for chronic liver disease, has announced the continued expansion of its commercial partnersh...

 April 30, 2026 | News

C-Ray Therapeutics Activates FDA DMF For Copper 64 Radiolabelling To Enable Global IND And NDA Submissions

DMF No. 43568 is now active and available for reference in global IND and NDA submissions C-Ray Therapeutics (Chengdu) Co., Ltd., announced that its Type ...

 April 30, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close